OvationLab Conducts Landmark Human Study on the Safety and Efficacy of BPC-157 in Adults with Chronic Pain 

Dallas, TX – March 17, 2025 – OvationLab proudly unveils the results of the first-ever human study evaluating the safety and efficacy of orally available BPC-157 as a dietary supplement. This study assessed Infiniwell BPC-157 Delayed Pro 500mcg in adults suffering from chronic pain, providing  pivotal insights into its therapeutic potential. 

Study Overview:

This one-month study evaluated 101 adults experiencing moderate to severe chronic pain. Participants  took one capsule twice daily on an empty stomach, with pain intensity, pain interference in daily life, and  overall quality of life measured before and after the study. 

The research, led by Dr. Chris D’Adamo PhD, Laurie Hofmann, MPH, and Tom Blue, adhered to rigorous methodology and data analysis. 

Expert Insights:

Dr. Chris D’Adamo stated, “We now have human data supporting what clinicians have long  observed—this study provides a strong foundation for BPC-157 as a supplement, and I’m eager to see  further research.”  

Future Research & Expansion:

As a patient-reported outcome study without a placebo arm, further research is needed. This study lays the  groundwork for: 

● An IRB-approved, placebo-controlled trial with peer-reviewed publication 

● Expansion into other promising areas observed in animal models, including digestive, brain and liver health

About OvationLab:

OvationLab pioneers innovative supplement research and development, delivering scientifically validated,  high-quality products to enhance health and wellness. 

For media inquiries, please contact: 

Laurie Hofmann, MPH

Partner, OvationLab

laurie@ovationlab.com

www.ovationlab.com